VC Firms Seek New FDA Review Path, User Fee For "Novel" Devices
This article was originally published in The Gray Sheet
Executive Summary
The National Venture Capital Association is in discussions with senior CDRH officials about establishing a separate, more efficient pre-market review pathway for especially novel devices, supported by a supplemental user fee
You may also be interested in...
CDRH's Innovation Pathway: A Quicker Route For Breakthrough Devices?
For a select few devices per year, FDA says it will speed up pre-market development times by intensifying staff efforts, with a particular focus on very early-stage, frequent interactions with product sponsors.
CDRH's Innovation Pathway: A Quicker Route For Breakthrough Devices?
For a select few devices per year, FDA says it will speed up pre-market development times by intensifying staff efforts, with a particular focus on very early-stage, frequent interactions with product sponsors.
FDA Device Chief Open To New Review Approaches For Novel Technologies
FDA device center director Jeffrey Shuren says the idea of creating a special review pathway for novel technologies is gaining momentum at CDRH.